1. Home
  2. IMRN vs AIMD Comparison

IMRN vs AIMD Comparison

Compare IMRN & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$0.97

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

AIMD

Ainos Inc.

HOLD

Current Price

$2.28

Market Cap

10.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMRN
AIMD
Founded
1994
1984
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
10.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IMRN
AIMD
Price
$0.97
$2.28
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
83.4K
50.8K
Earning Date
02-27-2026
03-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,777,422.00
$113,037.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
48.63
178.19
52 Week Low
$0.68
$1.61
52 Week High
$2.39
$4.50

Technical Indicators

Market Signals
Indicator
IMRN
AIMD
Relative Strength Index (RSI) 46.08 64.36
Support Level $0.93 $1.70
Resistance Level $1.05 $1.90
Average True Range (ATR) 0.10 0.11
MACD 0.02 0.04
Stochastic Oscillator 37.43 76.32

Price Performance

Historical Comparison
IMRN
AIMD

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

About AIMD Ainos Inc.

Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.

Share on Social Networks: